An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis

Abstract Background In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV 1 . This longitudinal study examined the association between MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) to prognostic parameters in CF. Method A cross-sectional survey of CF and control subjects; CF patients were followed up for a median of 49months. MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma. Results Seventy-three patients with CF, median age 22years, and 40 controls were recruited. Fifty-three of these CF patients were followed up. Prospectively, in CF subjects, plasma MMP-9 activity was adversely associated with FEV 1 (β −1.15 (95% CI −2.10, −0.20), p=0.019) and rate of FEV 1 decline, and plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 (1.91–7.04), p Conclusions These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for short- to medium-term FEV 1 decline and mortality in patients with CF.